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Abstract
Objective: Changes in maternal concentrations of the anti-angiogenic factors, soluble fms-like tyrosine kinase 1 (sFlt1) and
soluble endoglin (sEng), and the pro-angiogenic placental growth factor (PlGF) precede the development of preeclampsia in
healthy women. The risk of preeclampsia is reduced in women who smoke during pregnancy. The objective of this study
was to investigate whether smoking affects concentrations of angiogenic factors (sFlt1, PlGF, and sEng) in women at high
risk for developing preeclampsia.
Study Design: We performed a secondary analysis of serum samples from 993 high-risk women (chronic hypertension,
diabetes, multifetal gestation, and previous preeclampsia) in a preeclampsia prevention trial. sFlt1, sEng and PlGF were
measured in serum samples obtained at study entry, which was prior to initiation of aspirin (median 19.0 weeks’
[interquartile range of 16.0–22.6 weeks’]). Smoking status was determined by self-report.
Results: sFlt1 was not significantly different in smokers from any high-risk groups compared to their nonsmoking
counterparts. PlGF was higher among smokers compared to nonsmokers among diabetic women (142.7 [77.4–337.3] vs 95.9
[48.5–180.7] pg/ml, p = 0.005) and women with a history of preeclampsia (252.2 [137.1–486.0] vs 152.2 [73.6–253.7] pg/ml,
p = 0.001). sEng was lower in smokers with multifetal gestations (5.8 [4.6–6.5] vs 6.8 [5.5–8.7] ng/ml, p = 0.002) and trended
lower among smokers with diabetes (4.9 [3.8–5.6] vs 5.3 [4.3–6.3] ng/ml, p = 0.05). Smoking was not associated with a lower
incidence of preeclampsia in any of these groups.
Conclusions: In certain high-risk groups, smoking is associated with changes in the concentrations of these factors towards
a pro-angiogenic direction during early pregnancy; however, there was no apparent association between smoking and the
development of preeclampsia in our cohort.
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Introduction
Cigarette smoke exposure is associated with many adverse
pregnancy outcomes including preterm labor, preterm premature
rupture of membranes, placental abruption and fetal growth
restriction/low birth weight [1,2]. Paradoxically, smoking is
associated with a reduced risk of developing preeclampsia [3,4].
The mechanism(s) underlying this relationship remains unclear,
but one mechanism postulated is that smoking reduces circulating
levels of the anti-angiogenic protein soluble fms-like tyrosine kinase
(sFlt1).
An imbalance of circulating angiogenic factors, specifically an
increase in anti-angiogenic proteins, sFlt1 and sEng, and a
decrease in the pro-angiogenic protein, placental growth factor
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(PlGF), has been proposed as causing some of the clinical
manifestations of preeclampsia [5,6]. Levine et al. have reported
significantly lower PlGF and significantly higher sFlt1 and sEng
with preeclampsia, even predating its clinical manifestations [7,8].
Cigarette smoking also influences angiogenic factors with lower
circulating sFlt1 concentrations observed in nonpregnant and low
risk pregnant smokers [8–13]. Findings regarding the relationship
between smoking and maternal PlGF are inconsistent with some
studies demonstrating higher PlGF in pregnant smokers and others
showing no difference [8,11,13]. Data regarding sEng are scant
with one study suggesting that sEng concentrations may be lower
among healthy pregnant smokers [8].
The observations described above focus on low risk pregnancies.
There are even fewer data relating to women at high risk for
developing preeclampsia. We hypothesized that cigarette smoking
during pregnancy would be associated with a pro-angiogenic
milieu (lower sFlt1 and sEng as well as higher PlGF) in the
maternal circulation of women at high risk for preeclampsia (i.e.,
pregestational diabetes, chronic hypertension, multifetal gestation,
or previous preeclampsia). We also sought to determine the
relationship of smoking and the development of preeclampsia in
each of these groups.
Methods
Study population
We performed a secondary analysis of the Maternal-Fetal
Medicine Units Network multicenter randomized controlled trial
of low-dose aspirin for the prevention of preeclampsia in high-risk
women [14]. A total of 2,539 subjects from 13 participating
centers were enrolled between 1991 and 1995 and categorized in
four groups: those with pregestational diabetes, chronic hyperten-
sion, history of preeclampsia in a previous pregnancy, or multifetal
gestation. Subjects were included in the current analysis if they had
a study entry serum sample available.
High risk groups were defined as in the primary study [14].
Pregestational diabetics were classified based on insulin treatment
prior to pregnancy. The diagnosis of chronic hypertension required
medical record documentation of antihypertensive drug therapy or
a blood pressure measured in the sitting position equal to or greater
than 140/90 mmHg taken on two occasions at least four hours
apart, either before conception or during pregnancy but prior to
study entry and before gestational week 20. Previous preeclampsia
was defined as new-onset proteinuric hypertension after midgesta-
tion as determined by medical records or, in the absence of a record,
a history of preeclampsia that resulted in delivery before the 37th
gestational week. Multifetal gestation required documentation by
ultrasound examination before enrollment.
At the screening visit, all women underwent urinary protein
testing by dipstick. A 24 hour urine collection was obtained if a
value of 1+ or greater was detected. Abnormal proteinuria was
diagnosed when total protein excretion was $300 mg over
24 hours. Women with multifetal gestations were ineligible for
the study if they also had diabetes mellitus, chronic hypertension,
or proteinuria as defined above, as were women with a history of
preeclampsia and current proteinuria. Women with both diabetes
and hypertension were included in the diabetes group.
The diagnosis of preeclampsia was made as per the definitions
in the original study [14]. To ensure the validity of consistency in
the diagnosis of preeclampsia, the records of all women with
apparent preeclampsia in the original trial were independently
reviewed by three physicians unaware of treatment group
assignments (aspirin vs. placebo) and had to agree unanimously
on the validity of the designated outcome.
Subjects had provided written informed consent prior to
enrolling in the initial study. This investigation is a companion
to a study of the relationship between angiogenic factors and the
risk of preeclampsia in these groups [15]. Institutional Review
Board approval for the use of these stored samples was obtained at
both the University of Pittsburgh and George Washington
University. Laboratory assessment was completed at the Magee-
Womens Research Institute by investigators blinded to gestational
age and high risk category. Data was subsequently linked and
statistical analysis completed at the George Washington University
Biostatistics Center.
Determination of smoking status
Smoking status was determined through self-reporting at the
time of enrollment and/or sample collection. Subjects were asked
whether they had smoked cigarettes in the year prior to
pregnancy, whether they quit at the start of pregnancy, and if
they continued to smoke, whether they smoked more than a pack
of cigarettes per day. Serum cotinine concentrations were available
on a subset of the women.
Laboratory methods
Serum samples were assayed concurrently for sFlt1, sEng and
PlGF using commercially available immunoassay kits and each
sample run in duplicate according to the manufacturer’s protocol
(R&D Systems,Minneapolis, MN). All kits for each analyte were
from the same manufacturing lot in order to minimize variability.
Sensitivities for sFlt1, sEng, and PlGF were 0.005 ng/ml,
0.007 ng/ml, and 7 pg/ml, respectively. Of note, the sFlt assay
is specific for human sFlt1 and the PlGF assay does not cross react
with VEGF. In general, samples were diluted 1 to 5 for sFlt1 and
sEng, and 1 to 2 for PlGF in order for the samples to fall within the
measurable range of the kit’s standard curves. A small number of
samples needed to be re-analyzed because calculated values were
outside of the standard curve’s range. The inter-assay variability
was 10% for sFlt1, 11% for sEng and 7% for PlGF.
Statistical analysis
Data from each group were analyzed separately. Continuous
variables were compared using the Wilcoxon rank-sum test and
categorical variables using the chi-square test. Bivariate analysis
and multivariable logistic regression were used to determine the
association of smoking with the development of preeclampsia. All
p-values are two-tailed and a value of less than 0.05 was
considered statistically significant. No adjustments were made for
multiple comparisons. Analyses were performed using SAS
software.
Results
A total of 993 serum samples obtained at study entry (diabetes,
n = 194; chronic hypertension, n= 313; multifetal gestation,
n = 234; and previous preeclampsia, n = 252) were available for
analysis. The original trial included 2,539 women so this analysis
represents 39% of the women. Within each of the groups, women
in this analysis (i.e. women with a serum sample at study entry)
were similar to women not included (i.e. without a sample) for the
following characteristics: primigravid status, smoking, maternal
age and body mass index. Compared to women without samples,
there were slightly more Caucasians in the diabetes and multifetal
groups. The gestational age at study entry was also slightly earlier
compared to women without samples in the multifetal group.
Baseline demographic and clinical characteristics for each of the
four groups (pregestational diabetes, chronic hypertension, prior
Smoking and Preeclampsia
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preeclampsia, and multifetal gestation) are presented in Table 1.
Median gestational age at baseline sample collection was 19.0
weeks (interquartile range of 16.0–22.6). Overall, 163 women
(16.4%) reported that they were smokers at the time of the baseline
interview and 2.2% reported smoking one or more packs of
cigarettes per day. The percentage of smokers among diabetics,
chronic hypertensives, previous preeclamptics, and women with
multifetal gestations were 20%, 17%, 16%, and 13%, respectively.
We compared sFlt1, sEng, and PlGF concentrations between
pregnant smokers and nonsmokers in each of the four groups
separately (Tables 2–5). Women with diabetes who smoked had
higher circulating PlGF (142.7 [77.4–337.3] vs 95.9 [48.5–180.7],
p = 0.005), slightly lower soluble endoglin (4.9 [3.8–5.6] vs 5.3
[4.3–6.3], p = 0.05), and no difference in sFlt1 than those who did
not smoke. Among women with chronic hypertension, there were
no differences between smokers and nonsmokers in the three
angiogenic factors measured. Among women with preeclampsia in
a prior pregnancy, only PlGF was significantly higher in smokers
than in nonsmokers (252.2 [137.1–486.0] vs 152.2 [73.6–253.7],
p = 0.001). Among women with multifetal gestations, only sEng
was different (i.e., lower) in smokers compared to nonsmokers.
Given the higher sFlt1 and sEng, as well as lower PlGF
concentrations prior to and after recognition of preeclampsia in
low risk women, we also analyzed our data by removing women
who eventually developed preeclampsia. With the exclusion of 46
diabetic women, 78 chronic hypertensive women, and 39 women
with multifetal gestations who developed preeclampsia, there were
no changes in the relationship of sFlt1, sEng, or PlGF between
smokers and nonsmokers. When the 50 women who developed
preeclampsia were excluded from the group with prior preeclamp-
sia, sFlt1 was significantly lower in smokers compared to
nonsmokers (2.4 vs 3.1 ng/ml, p = 0.02), but the relationship of
PlGF and sEng between smokers and nonsmokers remained the
same.
Smoking in early pregnancy was not associated with a reduction
in the incidence of preeclampsia in any of the four groups using
bivariate analysis and multivariable logistic regression analysis
controlling for maternal age, race, BMI and treatment group
(aspirin or placebo) (Table 6).
Although we assessed maternal cigarette smoke exposure by
self-report, serum cotinine concentrations from a previous analysis
were available for 673 (68%) of the 993 serum samples analyzed.
In this cohort, the degree of agreement between self-report of
smoking status and a cotinine concentration of $10 ng/ml, a cut-
off representing active smoking[16], was high (kappa coeffi-
cient = 0.81); 95.5% of women who self-reported smoking had
cotinine concentrations of $10 ng/ml and 94.1% of self-reported
nonsmokers had concentrations ,10 ng/ml.
Discussion
We sought to describe the relationship between smoking,
angiogenic factors and preeclampsia in four well-defined high risk
pregnancy groups. The major findings of our study were (1) maternal
sFlt1 concentrations are not reduced with smoking, (2) smoking is
associated with changes in circulating PlGF and sEng concentrations
toward a pro-angiogenic direction but these differences were not
consistent across all high risk groups, and (3) smoking in early
pregnancy is not associated with a reduced incidence of preeclampsia.
We measured sFlt1, sEng and PlGF because of their proposed
pathologic role in preeclampsia and the influence of smoking on
their circulating levels during pregnancy. Based on consistent
reports of low sFlt1 in nonpregnant and healthy pregnant smokers,
we hypothesized and fully expected sFlt1 to be lower among
smokers in the high risk groups studied. However, this was not the
Table 1. Baseline characteristics of women at high risk for preeclampsia.*
Characteristics
Pregestational diabetes
(n =194)
Chronic hypertension
(n =313)
Previous preeclampsia
(n =252) Multifetal gestation (n =234)
Smoker
(n =39)
Nonsmoker
(n=155) p-value
Smoker
(n =53)
Nonsmoker
(n=260) p-value
Smoker
(n =40)
Nonsmoker
(n=212) p-value
Smoker
(n =31)
Nonsmoker
(n=203) p-value
Maternal age
(years)
2666 2666 0.64 3067 2967 0.18 2665 2465 0.02 2665 2566 0.21
Gestational age at
entry (weeks)
1863 1764 0.16 1964 1964 0.73 2064 2064 0.41 2164 2164 0.44
Primigravida,
n (%)
6 (15) 60 (39) ,0.01 7 (13) 58 (22) 0.14 0 (0) 0 (0) n/a 6 (19) 66 (33) 0.14
Race or ethnic
group, n (%)
0.47 0.07 0.03 ,0.01
Caucasian 27 (69) 91 (59) 17 (32) 66 (25) 15 (38) 40 (19) 19 (61) 73 (36)
African-American 10 (26) 51 (33) 35 (66) 162 (62) 24 (60) 166 (78) 12 (39) 102 (50)
Hispanic/other 2 (5) 13 (8) 1 (2) 32 (12) 1 (3) 6 (3) 0 (0) 28 (14)
Systolic blood
pressure at entry
(mmHg)
114614 114615 0.98 121614 129614 ,0.01 113613 111611 0.37 110610 112611 0.29
Diastolic blood
pressure at entry
(mmHg)
68610 68610 0.73 70613 78611 ,0.01 64611 6669 0.50 62610 6469 0.23
Body mass index
(kg/m2)
2767 2868 0.54 3167 3469 0.03 2868 2868 0.86 2667 2767 0.51
*Data are presented as mean 6 standard deviation or n (%).
doi:10.1371/journal.pone.0013270.t001
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case in any of the four groups. On the other hand, PlGF was
higher in smokers with pregestational diabetes and prior
preeclampsia compared to their nonsmoking counterparts and
sEng was lower in smokers with multifetal gestations and diabetes.
Excluding women who developed preeclampsia did not substan-
tially change our results, except that sFlt1 was lower in smokers
with prior preeclampsia compared with nonsmokers. We did not
analyze the data based on quantity of cigarette smoking because
only 2.2% of women in our cohort smoked greater than one pack
per day limiting any meaningful analyses based on dose response
of the number of cigarettes smoked and angiogenic factor
concentrations. All the significant differences were consistently in
a pro-angiogenic direction, i.e., higher PlGF and lower sEng
among smokers. While existing data are limited, higher PlGF and
lower sEng were also observed among smokers in a low risk
population [8,11]. PlGF concentrations also trended higher in
placental villous explants exposed to cigarette smoke extract,
lending biologic support for the effect of smoking on PlGF in
certain subgroups of our study [17]. Further evidence for the
potential pro-angiogenic effects of smoking is that smoking is
associated with acceleration of diabetic retinopathy [18].
The lack of consistent findings across the four groups is not
surprising as these are pathologically different disorders and their
contribution to pregnancy complications such as preeclampsia is
likely to be heterogeneous. For example, chronic hypertension is
primarily characterized by endothelial dysfunction and microvas-
cular disease whereas with diabetes the pathology may be due to
direct effects of hyperglycemia in addition to vascular disease.
Furthermore, the maternal versus fetal/placental contribution to
circulating angiogenic factors may be quite different, further
confounding any superimposed effect of smoking.
In low risk pregnancies, the association between cigarette
smoking and a reduced risk of preeclampsia has been a consistent
and reproducible finding across epidemiologic studies [3,4].
Therefore, we expected to find a similar relationship in the high
risk groups that we studied. We did not observe a significant
association between smoking in early pregnancy and reduced risk
of developing preeclampsia in any group. Our negative findings
may be attributed to the relatively small numbers in each group;
for example, among diabetic women and women with multifetal
pregnancies the point estimates are in the direction of a reduced
risk of preeclampsia but the confidence intervals are wide (0.40
[95% confidence interval, 0.15–1.12] in diabetics and 0.53 [0.15–
1.87] in the multifetal gestation group). A larger sample size may
lend more precision to the odds ratios for the relationship between
smoking and preeclampsia within each group. However, others
have also reported negative findings among various high risk
cohorts. Chappell and colleagues failed to find an association
between smoking and a lower rate of preeclampsia among chronic
hypertensive women and suggested that smoking may even be an
independent risk factor for superimposed preeclampsia [19]. The
lack of a significant association was also demonstrated among twin
pregnancies [20,21], overweight/obese women [22], African
American women [23], and older women [24]. Data regarding
smoking and preeclampsia in diabetic pregnancies are variable
with no mitigating effect in a large cohort of gestational diabetic
women [25], but a risk reduction in two smaller case series of
women with pregestational diabetes [26,27]. An alternative
explanation may be that smoking in early pregnancy may not be
associated with a lower incidence of preeclampsia. A recent study
by Wilkstrom and colleagues demonstrated that there was no
significant association of smoking and preeclampsia in women who
quit smoking prior to late pregnancy in a Swedish cohort of low
risk women [28,29]. The precise reason as to why smoking may be
Table 3. Comparison of angiogenic factors in pregnant
women with chronic hypertension: smokers versus
nonsmokers.*
Chronic hypertension
Smoker (n=53)
Nonsmoker
(n=260) p-value
sFlt1 (ng/ml) 3.1 (2.4–4.6) 3.0 (2.1–4.3) 0.52
sEng (ng/ml) 4.9 (4.3–5.4) 4.8 (4.2–5.9) 0.71
PlGF (pg/ml) 157.8 (111.3–260.7) 137.8 (70.9–282.0) 0.22
*Data are presented as median (inter-quartile range).
doi:10.1371/journal.pone.0013270.t003
Table 4. Comparison of angiogenic factors in pregnant
women with preeclampsia in a previous pregnancy: smokers
versus nonsmokers.*
Previous preeclampsia
Smoker (n=40)
Nonsmoker
(n =212) p-value
sFlt1 (ng/ml) 2.6 (1.9–3.6) 3.1 (2.2–4.0) 0.10
sEng (ng/ml) 4.6 (4.0–5.4) 5.0 (4.0–5.9) 0.44
PlGF (pg/ml) 252.2 (137.1–486.0) 152.2 (73.6–253.7) 0.001
*Data are presented as median (inter-quartile range).
doi:10.1371/journal.pone.0013270.t004
Table 5. Comparison of angiogenic factors in women with
multifetal gestations: smokers versus nonsmokers.*
Multifetal gestation
Smoker (n=31)
Nonsmoker
(n=203) p-value
sFlt1 (ng/ml) 5.2 (4.2–6.6) 6.0 (4.2–7.7) 0.11
sEng (ng/ml) 5.8 (4.6–6.5) 6.8 (5.5–8.7) 0.002
PlGF (pg/ml) 491.2 (211.0–728.5) 403.5 (229.2–756.8) 0.40
*Data are presented as median (inter-quartile range).
doi:10.1371/journal.pone.0013270.t005
Table 2. Comparison of angiogenic factors in pregnant
women with pregestational diabetes: smokers versus
nonsmokers.*
Pregestational diabetes
Smoker (n =39)
Nonsmoker
(n =155) p-value
sFlt1 (ng/ml) 3.0 (2.5–4.2) 3.3 (2.2–4.4) 0.99
sEng (ng/ml) 4.9 (3.8–5.6) 5.3 (4.3–6.3) 0.05
PlGF (pg/ml) 142.7 (77.4–337.3) 95.9 (48.5–180.7) 0.005
*Data are presented as median (inter-quartile range).
doi:10.1371/journal.pone.0013270.t002
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associated with a lower rate of preeclampsia in low risk but not
high risk women is not known, but we speculate that the
underlying pathology increases the risk of preeclampsia to such a
degree that any measurable effect of smoking is superceded.
As previously mentioned, sample size within each group and the
retrospective approach are limitations of our study. Importantly,
the inability to assess smoking status across pregnancy and account
for changes in smoking patterns may affect circulating angiogenic
factors and subsequent risk of preeclampsia. Despite these
limitations, our study is novel in addressing the relationship
between smoking and angiogenic factors as well as smoking and
preeclampsia among groups of women at high risk for developing
preeclampsia. A particular strength of this study is that the groups
and the diagnostic criteria for preeclampsia are well defined as
described in the original Maternal-Fetal Medicine Units Network
trial [14]. All samples in this study were analyzed in a blinded
fashion. Furthermore, we confirm self-report of smoking with
cotinine concentrations in a subpopulation, thereby reducing
misclassification bias [30]. Our results do not address mechanistic
pathways by which smoking may affect certain angiogenic factors
in these groups of women at high risk for preeclampsia. Further
study is warranted to better define the biological mechanisms and
complex interactions within specific groups and potential reasons
for the differences we observed.
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